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Figure S1. Effect of caspase inhibitor zVAD−fmk cell death (percent of Trypan blue-
positive cells) in U87MG (top) and T98G (bottom) cells treated with (left to right): G5, 2h, 
1b. Columns, mean (n = 3); bars, SD.  
 
 
 
 
 
 
 
 
 
 
Figure S2. A) Immunoblot analysis showing poly-ubiquitin accumulation, p53 stabilization 
and Noxa induction in A549 cells treated with 10 µM 2c and 2cPE (11) for 6-48 hours. B) 
Poly-ubiquitin accumulation, p53 stabilization and Noxa induction in A375 cells treated 
with 2.5-10 µM 2c and 11 for 24 hours. 
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Figure S3. Responsiveness of HT29 cells to 2c and 2cPE treatments.  
A) HT29 cells were treated with the indicated concentrations of 2c (grey columns) and 2cPE 
(11) (black columns) for 48 h. Appearance of cell death was scored by trypan blue staining. 
Columns, mean (n = 3); bars, SD.  
B) HT29 cells were treated with 10µM 2c and 2cPE (11) for 48 h in a normal medium and 
in  a conditioned medium from A375 cell cultures. Appearance of cell death was scored by 
trypan blue staining. Columns, mean (n = 3); bars, SD.  
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Figure S4. RT-PCR analysis to verify the expression of recombinant PLA2G7 in A549 
cells. RNAs were extracted, retro-transcribed and PLA2G7 ORF amplified using Taq 
polymerase and the corresponding oligonucleotides. GAPDH was amplified as control. In 
the control PCR was performed in the absence of RNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S5.  Body weight variations of mice treated with 200-800 mg/kg 2cPE, showing no 
gross toxicity after 18 days.  
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Animal studies 
Three to four animals were housed in each cage. The animals were kept in a controlled 
environment, with a light/dark cycle of 12 hours (h) each. Sterile tap water and sterile food 
was provided ad libitum. All animals were subjected to the same environmental conditions.  
 
 
 
Microarray data processing and analysis 
CDFs were downloaded from the Molecular and Behavioral Neuroscience Institute 
Microarray Lab (URL:http:// brainarray.mbni.med.umich.edu/ Brainarray/ Database/ 
CustomCDF/genomic_curated_CDF.asp). All annotation information were downloaded 
from the same website.  The normalization step was done with the standard MAS5.0 
algorithm, described in the Statistical Algorithms Description Document available from 
Affymetrix (URL: http:// www.affymetrix.com/ support/ technical/ whitepapers/ 
sadd_whitepaper.pdf). 
 
 
 
Modeling of the PLA2G7 catalyzed hydrolysis of PEGylated 2c. The model was built 
from the crystal structure of PLA2G7 covalently inhibited by paraoxon (PDB: 3D5E) 
following the logical scheme shown in Figure S5.  
 
Figure S6. Logical scheme for the construction of a model of the tetrahedral 
intermediate for the phospholipase 2A catalysed hydrolysis of 2cPE 
 
Starting the 3D5E crystal structure, initially all the hydrogen atoms were added assuming a 
pH environment of 7.5, then all the crystallization water molecules were removed, and this 
reference complex (C1, Figure S5) was allowed to relax. The initial geometry of the enzyme 
tetrahedral intermediate was built by docking a simplified substrate (acetylated 2c) onto the 
structure of the phosphonate portion of the optimized reference complex C1. Both possible 
configurations at the reactive carbon were considered, and the conformational space 
accessible to the tetrahedral intermediates was explored. A set of sterically tolerable 
conformations was generated by a systematic search carried out on all the rotatable bonds of 
the serine-bound intermediates, and only the S intermediate C2 gave low energy relaxed 
structures. The unique conformation corresponding to a productive intermediate was then 
selected by structural analysis: the stereoelectronic theory of Deslongchamps predicts that in 
a tetrahedral intermediate for ester hydrolysis, the C–O bond can be cleaved efficiently only 
if both the remaining oxygens of the intermediate have a lone pair orbital antiperiplanar to 
the breaking bond (Figure S6).1  
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Figure S7. Productive conformation of the intermediate for ester hydrolysis  
 
This condition has proven to be effective in explaining the selectivity of lipase catalyzed 
reactions2 and it is satisfied only if the geometry around the O(Ser273)–C–O–R dihedral 
angle is anti, as in C2. In our case this conformation may be obtained in a unique way 
without the occurrence of unfavourable contacts. It also allows establishing the optimal 
hydrogen bond network between the oxyanion hole residues and the intermediate, which 
was then optimized starting from this geometry. After this first stage, a succinate moiety 
esterified with a polyethylene glycol dodecamer was added in order to mimic 2cPE. The 
chain was easily placed inside the channel leading to the hydrophobic interface, and the 
whole structure C2 thus obtained was finally optimized. 
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Synthesis and characterization of compounds 1a, 2a, 2b, 2e. 
 
 
 
 
(3Z,5Z)-3,5-Bis(benzylidene)-tetrahydro-4H-thiopyran-4-one-1,1-dioxide (1a).  21% 
from tetrahydro-4H-thiopyran-4-one-1,1-dioxide and benzaldehyde, following the literature 
procedure;3 m.p. 195–198 °C (lit.3 198–200 °C). 1H NMR: δ = 4.44 (s, 4H), 7.45 (m, 10H), 
8.0 ppm (s, 2H). 13C NMR: δ = 53.2, 126.8, 129.1, 129.7, 130.1, 133.6, 144.3, 186.3 ppm. 
IR: ν = 1664 (SO2), 1325 and 1128 cm-1 (SO2). MS: m/z 324 (M+ 30%), 259 (100%). 
 
 
 
(2E,6E)-2,6-Bis[(4-nitrophenyl)methylene]cyclohexanone (2a). 70% from cyclohexanone 
and 4-nitrobenzaldehyde, following the literature procedure;4 m.p. 200–203 °C. 1H NMR: δ 
= 1.84 (m, 2H), 2.92 (m, 4H), 7.58 (d, 4H), 7.79 (s, 2H), 8.26 ppm (d, 4H). 13C NMR: δ = 
22.6, 28.4, 123.8, 130.8, 134.9, 138.7, 142.2, 147.4, 189.3 ppm. IR: ν = 1670 (C=O), 1513 
and 1342 cm-1 (NO2). MS: m/z 364 (M+ 10%). 
 
 
(7E,9E)-7,9-Bis[(4-nitrophenyl)methylene]-1,4-dioxaspiro[4,5]decan-8-one (2b). 52% 
from 1,4-dioxaspiro[4,5]decan-8-one and 4-nitrobenzaldehyde, following the literature 
procedure;4 m.p. 243 °C (from ethanol) (lit.4 244–246 °C). 1H NMR: δ = 3.0 (s, 4H), 3.85 
(m, 4H), 7.58 (d, 4H), 7.8 (s, 2H), 8.25 ppm (d, 4H).  13C NMR: δ = 37.8, 65.1, 106.0, 
123.6, 130.8, 135.4, 136.4, 141.8, 147.0, 187.0 ppm. IR: ν = 1676 (C=O), 1519 and 1342 
cm-1 (NO2). MS: m/z 422 (M+ 100%). 
 
 
(3E,5E)-3,5-Bis[(4-nitrophenyl)methylene]-4-piperidone (2e). 45% from 4-piperidone 
hydrochloride monohydrate and 4-nitro-benzaldehyde, following the literature procedure;5 
m.p. 233–235 °C (lit.5 230–233 °C). 1H NMR  ([D6]DMSO): δ = 4.0 (s, 4H), 7.65 (s, 2H), 
7.76 (d, 4H), 8.27 ppm (d, 4H). 13C NMR ([D6]DMSO): δ = 47.96, 124.14, 131.90, 132.13, 
139.58, 142,00 147.66, 198.38 ppm. IR: ν = 3310 (NH), 1661 (C=O), 1520 and 1352 cm-1 
(NO2). ESI-MS: 388 (MNa+), 366 (MH+).    
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HPLC analysis of tested compounds.  
All the compounds were analysed on a Phenomenex Luna C18 5µ 150x4.6 mm column. 
The composition of the mobile phase is reported in table S1 with the retention times and the 
% area of the main peak. The flow was always 1 ml/min. 20 µl of a 100 µM solution of the 
compound in acetonitrile were loaded on the column. An UV detector set at 230 nm was 
used.  
 
Table S1. Mobile phase, retention time and purity of tested compounds. 
 
Compound Water Acetonitrile Rt/min % 
1a 60 40 15.91 99.9 
1b 60 40 58.25 99.7 
1c 45 55 2.46 96.2 
1d 45 55 7.38 98.5 
1e 45 55 11.81 98.2 
1f 35 65 4.54 97.1 
1g 35 65 3.39 97.7 
1h 35 65 5.52 98.3 
1i 35 65 3.84 97.9 
1j 35 65 5.90 97.7 
1k 35 65 9.40 97.7 
1l 35 65 6.91 96.8 
G5 50 50 10.78 99.1 
     
2a 35 65 10.74 99.2 
2b 60 40 30.92 98.8 
2c 55 45 11.79 98.8 
2d 55 45 40.23 95.7 
2f 50 50 22.97 98.4 
2g 50 50 37.19 96.7 
2h 50 50 6.19 97.3 
 
 
